An established molecular-targeted therapy paradigm in childhood ALL is Philadelphia positive (Ph+) ALL with the t(9;22)(q34;q11) resulting in BCR-ABL1 oncoprotein. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.